Vol. 7, Issue 1, Part C (2025)

Background: Acute Coronary Syndrome functions as the primary mortality-causing medical condition worldwide. Cystatin C serves as an essential biomarker for risk assessment which leads to better patient results. Research shows Cystatin C functions as a prospective cardiovascular event indicator but scientists have not determined its effectiveness in ACS outcome prediction.
Objective: The research examines the predictive value of Cystatin C measurements among ACS patients through assessment of their relationship to in-hospital death statistics and heart electrical problems together with left ventricular ejection fraction and hospital readmission rates.
Methods: Researchers performed this prospective study for 51 ACS patients who received admission treatment at Merjan Teaching Hospital from March to July 2015. Research investigators used the nephelometric-immunoturbidimetric method to determine Cystatin C levels. The research team tracked mortality statistics and electrical complications as well as left ventricular ejection fraction and rates of rehospitalization across all participants. The study utilized SPSS version 20 for statistical analysis which regarded results significant at p≤0.05.
Results: A high Cystatin C level in patients directly correlated to a higher death rate during hospitalization (p = 0.009). The study results showed that patients with increased Cystatin C concentrations had a statistically significant connection to electrical complications (p = 0.035). Cystatin C levels demonstrated a negative association with left ventricular ejection fraction and positively associated with the need for rehospitalization (p = 0.01). The research did not show a meaningful relationship between Cystatin C levels and ventricular septal rupture occurrence (p = 0.1).
Conclusion: ACS patients with increased Cystatin C levels demonstrate higher death rates together with elevated electrical complications as well as lower left ventricular ejection fraction and greater chance of hospital readmission. Examination of Cystatin C proves its clinical value as an early risk stratification and management decision-making biomarker for ACS treatments.